Eindhoven-based medtech developer Sirius Medical has announced the successful closing of a series B round, raising 12 million euros in additional funding. The money is earmarked to accelerate the worldwide growth of the Pintuition tumor localization solution and support further product development. Holland Capital acted as the lead investor for this series B with support from existing investors BOM Brabant Ventures, Curie Capital, Team Holmium and a major capital injection from Sirius’s management and team. Norgine Ventures has joined as a new investor to support the further commercial rollout.
Pintuition provides surgeons with real-time distance and directional navigational guidance using audio and visual feedback to locate non-palpable tumors. The multi-sensor technology tracks a tiny permanent magnetic seed that marks the cancer and helps with surgical removal from any direction. According to Sirius, its solution is precise, simple and affordable, while being both CE marked and FDA cleared.
With over 100 active centers and more than 5,000 successful procedures across Western Europe and the US, Sirius experienced unprecedented revenue growth in 2022. “We’re excited about the market potential for surgical marker navigation,” says Jan Frens van Giessel, partner at Holland Capital. “We believe that the Pintuition technology and its future innovations will significantly improve surgery of non-palpable tumors for patients and physicians and improve the care for cancer patients.”